• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Antineoplastic combined chemotherapy protocols"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 115

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study 

      Kalofonos, H. P.; Kardamakis, D.; Bamias, A. T.; Skarlos, Dimosthenis V.; Papakostas, P.; Bafaloukos, Dimitrios; Sakantamis, A.; Pavlidis, Nicholas; Fountzilas, George (2003)
      Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...

    • Article  

      Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study 

      Fountzilas, George; Stathopoulos, G. P.; Kouvatseas, G.; Polychronis, A.; Klouvas, G. D.; Samantas, E.; Zamboglou, N.; Kyriakou, K.; Adamou, A.; Pectasides, Dimitrios; Economopoulos, T.; Kalofonos, H. P.; Bafaloukos, Dimitrios; Georgoulias, V.; Razi, E. D.; Koukouras, D.; Zombolas, V.; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2004)
      The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...

    • Article  

      Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience 

      Pectasides, Dimitrios; Fountzilas, George; Aravantinos, Gerasimos; Kalofonos, H. P.; Efstathiou, E.; Farmakis, D.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Economopoulos, T.; Dimopoulos, M. A. (2006)
      Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...

    • Article  

      Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study 

      Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)
      We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

    • Article  

      Cancer of unknown primary: What kind of chemotherapy? what kind of disease? 

      Pentheroudakis, George; Pavlidis, Nicholas (2009)

    • Article  

      Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study 

      Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)
      We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...

    • Article  

      Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study 

      Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

    • Article  

      CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature 

      Briassoulis, E. Ch; Kamposioras, K.; Tzovaras, V.; Pafitanis, G.; Kostoula, A.; Mavridis, A. K.; Pavlidis, Nicholas (2008)
      We report on a small-cell lung cancer case that was heralded by the presence of CENP-B specific anti-centromere autoantibodies (ACA) detected well before the diagnosis of cancer. The patient received chemotherapy plus ...

    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study 

      Kosmidis, Paraskevas A.; Samantas, E.; Fountzilas, George; Pavlidis, Nicholas; Apostolopoulou, F.; Skarlos, Dimosthenis V. (1994)
      The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...

    • Article  

      Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study 

      Tsavaris, N.; Primikirios, N.; Mylonakis, N.; Varouchakis, G.; Dosios, T.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Tasopoulos, T.; Dritsas, J.; Kosmidis, Paraskevas A. (1997)
      From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...

    • Article  

      Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma 

      Tsavaris, N.; Mylonakis, N.; Karvounis, N.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Stamatelos, G.; Kosmidis, Paraskevas A. (1994)
      From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...

    • Article  

      Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group 

      Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)
      To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

    • Article  

      Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer 

      Samantas, E.; Skarlos, Dimosthenis V.; Pectasides, Dimitrios; Nikolaidis, Pavlos; Kalofonos, H. P.; Mylonakis, N.; Vardoulakis, Th; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Fountzilas, George (1999)
      Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...

    • Article  

      Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study 

      Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)
      Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

    • Article  

      Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)
      Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

    • Article  

      Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study 

      Briassoulis, E. Ch; Tsavaris, N.; Fountzilas, George; Athanasiades, A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Pavlidis, Nicholas (1998)
      The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...

    • Article  

      Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis 

      Golfinopoulos, Vassilis; Pentheroudakis, George; Salanti, G.; Nearchou, A. D.; Ioannidis, J. P. A.; Pavlidis, Nicholas (2009)
      Objectives: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). Data sources: PubMed and the Cochrane Library Central ...

    • Article  

      Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients 

      Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)
      362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...

    • Article  

      The diagnostic and therapeutic management of leptomeningeal carcinomatosis 

      Pavlidis, Nicholas (2004)

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD